HEADACHE/MIGRAINE RESEARCH

C-BEOND (23-1244)

• Investigator: Danielle Wilhour, MD
• Purpose: to test how well Dysport® works and how safe it is compared with placebo (dummy drug) in preventing or decreasing migraines.
• Intervention: participant will receive for 4 cycles with either one of the two doses of Dysport®, or with 2 placebo cycles followed by 2 cycles with one of the two doses of Dysport®, depending on your assigned study treatment arm.
• Timeline: Screening Period: 6-12 weeks and Study Treatment Period: 48 weeks.
• ClinicalTrials.gov Identifier: NCT06047444
  
• Key Eligibility Criteria:
  • Age: ≥18 years
  • Diagnosis: Chronic Migraine for more than 12 months
  • Migraine onset occurred when participant was <50 years of age